Skip to content
52
PricingSign in

Connections

Request that the FDA, acting through its Center for Veterinary Medicine ("CVM"), exercise its post-approval oversight authority to impose enforceable safe-use conditions for Librela (bedinvetmab injection) (NADA 141-562), a caninized monoclonal antibody approved for the control of pain associated with osteoarthritis in dogs

1 recorded connections shown. Select a record, office or person to follow its source references.

Start with
and connect to

Browse all held record sources

Zoom to read. Drag to explore. Select a connection.

Request that the FDA, acting through its Center for Veterinary Medicine ("CVM"), exercise its post-approval oversight authority to impose enforceable safe-use conditions for Librela (bedinvetmab injection) (NADA 141-562), a caninized monoclonal antibody approved for the control of pain associated with osteoarthritis in dogs

Dockets · As of Jun 30, 2026

Dockets
Request that the FDA, acting through its Center for Veterinary Medicine ("CVM"), exercise its post-approval oversight authority to impose enforceable safe-use conditions for Librela (bedinvetmab injection) (NADA 141-562), a caninized monoclonal antibody approved for the control of pain associated with osteoarthritis in dogs: 1 outgoing connections shown. Point at anyone to see how they are linked.Showing bounded source connections. Dates come from the held records; missing relationships remain unknown.

The source record

As of Jun 30, 2026; may be out of date.

Docket type
Nonrulemaking
Title
Request that the FDA, acting through its Center for Veterinary Medicine ("CVM"), exercise its post-approval oversight authority to impose enforceable safe-use conditions for Librela (bedinvetmab injection) (NADA 141-562), a caninized monoclonal antibody approved for the control of pain associated with osteoarthritis in dogs
Ingested at
2026-06-30T05:20:00.498608+00:00

Every link on this map

The same connections as a table, with the reason each one is here.

Connections of Request that the FDA, acting through its Center for Veterinary Medicine ("CVM"), exercise its post-approval oversight authority to impose enforceable safe-use conditions for Librela (bedinvetmab injection) (NADA 141-562), a caninized monoclonal antibody approved for the control of pain associated with osteoarthritis in dogs
DocketsWhat this connects toRequest that the FDA, acting through its Center for Veterinary Medicine ("CVM"), exercise its post-approval oversight authority to impose enforceable safe-use conditions for Librela (bedinvetmab injection) (NADA 141-562), a caninized monoclonal antibody approved for the control of pain associated with osteoarthritis in dogs has a recorded connection to Dockets.None